Frontiers in Oncology (Feb 2022)

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

  • Alberto Ocaña,
  • Alberto Ocaña,
  • Alberto Ocaña,
  • Jose Ignacio Chacón,
  • Jose Ignacio Chacón,
  • Lourdes Calvo,
  • Lourdes Calvo,
  • Antonio Antón,
  • Antonio Antón,
  • Mauro Mansutti,
  • Joan Albanell,
  • Joan Albanell,
  • Joan Albanell,
  • Joan Albanell,
  • María Teresa Martínez,
  • María Teresa Martínez,
  • María Teresa Martínez,
  • Ainhara Lahuerta,
  • Ainhara Lahuerta,
  • Giancarlo Bisagni,
  • Begoña Bermejo,
  • Begoña Bermejo,
  • Begoña Bermejo,
  • Vladimir Semiglazov,
  • Marc Thill,
  • Arlene Chan,
  • Serafin Morales,
  • Serafin Morales,
  • Jesús Herranz,
  • Ignacio Tusquets,
  • Ignacio Tusquets,
  • Ignacio Tusquets,
  • Massimo Chiesa,
  • Rosalía Caballero,
  • Pinuccia Valagussa,
  • Giampaolo Bianchini,
  • Emilio Alba,
  • Emilio Alba,
  • Emilio Alba,
  • Luca Gianni

DOI
https://doi.org/10.3389/fonc.2021.827625
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundDerived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receiving neoadjuvant chemotherapy (CT).MethodsThis is a retrospective analysis of two randomized studies involving early stage/locally advanced TNBC patients receiving anthracycline/taxane-based CT+/−carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils to the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR.ResultsIn total, 308 TNBC patients were analyzed, 216 from ETNA and 92 from GEICAM/2006-03. Baseline median dNLR was 1.61 (interquartile range (IQR): 1.25–2.04) and at EOT 1.53 (IQR: 0.96–2.22). Baseline dNLR showed positive correlation with increased tumor size (p-value = 1e−04). High baseline dNLR, as continuous variable or using median cutoff, was associated with lower likelihood of pCR in univariate analysis. High EOT dNLR as continuous variable or using quartiles was also associated with lower pCR rate in uni- and multivariate analyses.ConclusionsHigh baseline and EOT dNLR correlates with lower benefit from neoadjuvant CT in TNBC.

Keywords